Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100T65H
Period2023-01-01 → 2023-12-31
Filed2024-03-29
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥63m2023-01-01 → 2023-12-31StandaloneNet sales
Revenue¥976m2022-01-01 → 2022-12-31StandaloneNet sales
Revenue¥642m2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥314m2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Revenue¥1.3bn2019-01-01 → 2019-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.9bn2023-01-01 → 2023-12-31StandaloneOperating income
Operating income−¥1.2bn2022-01-01 → 2022-12-31StandaloneOperating income
Ordinary income−¥1.9bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31StandaloneOrdinary income
Ordinary income−¥1.5bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.7bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥539m2019-01-01 → 2019-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.9bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Profit before tax−¥1.1bn2022-01-01 → 2022-12-31StandaloneIncome before income taxes
Net income−¥1.9bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income−¥1.1bn2022-01-01 → 2022-12-31StandaloneProfit loss
Net income−¥1.6bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income−¥2.1bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Net income−¥912m2019-01-01 → 2019-12-31dStandaloneNet income loss (5-year summary)
Total assets¥2.0bnat 2023-12-31StandaloneAssets
Total assets¥2.7bnat 2022-12-31StandaloneAssets
Total assets¥4.3bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥2.8bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total assets¥4.4bnat 2019-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥567mat 2023-12-31StandaloneLiabilities
Total liabilities¥492mat 2022-12-31StandaloneLiabilities
Net assets / equity¥1.5bnat 2023-12-31StandaloneNet assets
Net assets / equity¥2.2bnat 2022-12-31StandaloneNet assets
Net assets / equity¥3.6bnat 2021-12-31dStandaloneNet assets
Net assets / equity¥2.0bnat 2020-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥3.5bnat 2019-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥1.5bnat 2023-12-31StandaloneCash and deposits
Cash and deposits¥1.7bnat 2022-12-31StandaloneCash and deposits
Cash & equivalents¥1.3bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.5bnat 2022-12-31StandaloneCash and cash equivalents
Cash & equivalents¥3.2bnat 2021-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥1.8bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥3.1bnat 2019-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.3bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.7bn2022-01-01 → 2022-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.7bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.5bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥238m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥5m2023-01-01 → 2023-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥20m2022-01-01 → 2022-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥942,0002021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥38m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥4m2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.1bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥114m2022-01-01 → 2022-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥3.1bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥242m2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2019-01-01 → 2019-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-108.922023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-66.312022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-95.52021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-145.582020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-65.552019-01-01 → 2019-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥74.35at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥124.2at 2022-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥206.86at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥136.43at 2020-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥240.71at 2019-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio71.5%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio81.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio83.6%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio71.4%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio78.7%at 2019-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued19,717,100at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued17,405,200at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued17,405,200at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued14,641,900at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued14,331,300at 2019-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees34at 2023-12-31StandaloneNumber of employees
Employees33at 2022-12-31StandaloneNumber of employees
Employees33at 2021-12-31dStandaloneNumber of employees
Employees32at 2020-12-31dStandaloneNumber of employees
Employees27at 2019-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 843
ItemContextValueUnit
Net cash provided by used in financing activitiesCurrentYearDuration_NonConsolidatedMember1142542000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YearDuration_NonConsolidatedMember67413000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYearDuration_NonConsolidatedMember21334000JPY
Net increase decrease in cash and cash equivalentsPrior1YearDuration_NonConsolidatedMember-1743434000JPY
Net increase decrease in cash and cash equivalentsCurrentYearDuration_NonConsolidatedMember-178437000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember3209635000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember1466201000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember1466201000JPY
Cash and cash equivalentsCurrentYearInstant_NonConsolidatedMember1287763000JPY
Directors compensations sgaPrior1YearDuration_NonConsolidatedMember90778000JPY
Directors compensations sgaCurrentYearDuration_NonConsolidatedMember101308000JPY
Salaries and allowances sgaPrior1YearDuration_NonConsolidatedMember231696000JPY
Salaries and allowances sgaCurrentYearDuration_NonConsolidatedMember200165000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember947491000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember1351940000JPY
Business consignment expenses sgaPrior1YearDuration_NonConsolidatedMember80294000JPY
Business consignment expenses sgaCurrentYearDuration_NonConsolidatedMember84542000JPY
Taxes and dues sgaPrior1YearDuration_NonConsolidatedMember20862000JPY
Taxes and dues sgaCurrentYearDuration_NonConsolidatedMember25552000JPY
License fee sgaPrior1YearDuration_NonConsolidatedMember29395000JPY
License fee sgaCurrentYearDuration_NonConsolidatedMember31293000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember947491000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember1351940000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2024-03-29
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第20期(自　2023年１月１日　至　2023年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Company name in english cover pageFilingDateInstantOncolys BioPharma Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　浦田　泰生
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03－5472－1578(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)経理・財務部長　　米尾　哲治
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03－5472－1578(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)経理・財務部長　　米尾　哲治
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE30058
Fund codeFilingDateInstant－
Security codeFilingDateInstant45880
Filer name in japaneseFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Filer name in englishFilingDateInstantOncolys BioPharma Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2022-12-31pass
balance sheet identitynon_consolidated 2023-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2021-12-31pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · operating cash flownon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass